LifeVantage Corporation — Form 10-Q Summary
Business context and period: The filing covers the first quarter of fiscal 2014, the three months ended September 30, 2013, compared with the three months ended September 30, 2012. LifeVantage sells dietary supplements and skincare products through independent distributors and preferred customers in the Americas and Asia/Pacific.
Financial performance and liquidity
| Metric | Quarter ended Sep. 30, 2013 | Prior-year quarter |
|---|---|---|
| Net sales | $51.3 million | $52.9 million |
| Gross profit / margin | $43.5 million / 84.8% | $45.1 million / 85.2% |
| Operating income | $5.1 million | $6.9 million |
| Net income | $3.3 million | $4.2 million |
| Diluted EPS | $0.03 | $0.03 |
| Cash provided by operations | $4.9 million | $0.9 million |
- Cash and cash equivalents were $28.0 million at September 30, 2013, up from $26.3 million at June 30. Working capital was $26.5 million, compared with $25.4 million at June 30.
- Investing activities used $0.3 million, primarily for fixed-asset purchases. Financing activities used $2.6 million, mainly for share repurchases, partly offset by option and warrant proceeds.
- There was no outstanding debt at September 30. Total liabilities were $19.4 million. Current assets were $44.9 million and current liabilities were $18.4 million.
- Sales and marketing expense was $30.2 million; general and administrative expense was $7.4 million; research and development was $0.3 million. Income tax expense was $1.9 million.
Material changes versus the prior-year quarter
- Revenue declined $1.5 million (about 2.9%). Management attributed the decline primarily to a 19.3% adverse impact from yen weakness on yen-based revenue. Americas sales increased $2.2 million, while Asia/Pacific sales decreased $3.7 million.
- Americas revenue rose to $34.5 million from $32.3 million; Asia/Pacific revenue fell to $16.8 million from $20.6 million. Japan sales declined to $14.6 million from $19.5 million.
- Gross margin slipped 0.4 percentage points, primarily due to higher international shipping costs. Operating income declined as sales and marketing and depreciation and amortization costs increased.
- Active independent distributors increased 24.1% to 67,000; active preferred customers increased 1.5% to 139,000.
- Operating cash flow increased from $0.9 million to $4.9 million. The filing attributes cash-flow movements in part to working-capital changes.
Outlook, risks and unusual items
- Management stated that cash balances and expected operating cash flow were sufficient for at least the next 12 months as of the reporting date. No numerical revenue or earnings guidance was provided.
- Subsequent financing and tender offer: On October 18, 2013, the company entered into a facility with a term loan of up to $47 million and a delayed-draw term loan of up to $20 million. Loans bear interest at 7.5% plus the greater of 1.25% or LIBOR, or an alternative reference rate plus 6.5%; substantially all assets secure the facility. On November 1, the company accepted 16,326,530 shares for $40 million in its modified Dutch auction tender offer. These events occurred after quarter-end and were not reflected in September 30 balances.
- During the quarter, the company repurchased 1.16 million shares for approximately $2.9 million; it reported that the $5 million authorization was fully used. The post-quarter tender offer is a separate, substantially larger capital transaction.
- Foreign exchange is a significant exposure, particularly yen weakness, given the company’s substantial Japan business. Approximately 35% of quarterly sales were outside the United States. Cash of $15.4 million was held primarily at one financial institution, and balances exceeded federally insured limits.
- The filing identifies risks from reliance on distributors, product and regulatory compliance, international operations, and dependence on key products. The new credit facility adds debt-service requirements, collateral and restrictive covenants, including financial covenants; a breach could trigger acceleration.
- The product-return reserve increased to approximately $1.0 million from $0.6 million at June 30. Management said routine lawsuits and disputes were not expected to have a material impact and considered adverse outcomes remote; the legal-proceedings section reported none. No off-balance-sheet arrangements were reported.
- Management concluded disclosure controls were effective at September 30 and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- How the $40 million tender offer and associated borrowing affected post-quarter cash, debt, interest expense, and shares outstanding.
- The final amount drawn under the $47 million term loan and whether the company uses the delayed-draw facility; review the facility’s covenants and repayment terms.
- Whether distributor growth translates into sustained sales, especially given the decline in Asia/Pacific and Japan revenue.
- The sensitivity of reported results to yen movements and the company’s approach to currency risk management.
- Whether the higher product-return reserve, international shipping costs, or distributor-related costs materially affect future margins and cash flow.